New EU supply chain to end Visudyne shortage
Safety Classified by Officially
A new supply chain for Visudyne (verteporfin) has been put in place in the European Union (EU), marking an important step towards resolving a long-standing shortage of the medicine. Approval of the new supply arrangements, including the registration of new manufacturing sites, has now been finalised, clearing the path to fully restore supply levels across the EU in 2027. Visudyne is an injectable medicine used to treat adults with certain serious eye conditions, including the ‘wet’ form of age-related macular degeneration and choroidal neovascularisation caused by pathologic myopia.
Resolving the shortage requires efforts to strengthen and diversify the supply chain, which until now has relied on a single US-based site for production of the active substance. The European medicines regulatory network supported the company’s work to establish the additional manufacturing sites that are expected to end the current controlled distribution system. This system was a key shortage mitigation measure taken by the Medicine Shortages Single Point of Contact (SPOC) Working Party and the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) to evenly allocate limited supplies between Member States and help ensure the medicine reaches patients who need it most. Regulatory flexibilities and support were also provided by the rapporteur team and EMA staff.
This situation shows the complexity of shortages and how coordination between the European Commission, EU Member States, MSSG and SPOC Working Party can ensure fair allocation of medicines, mitigate impact and prevent future shortages.
Medicine shortages can have serious consequences for patients and public health and place a heavy burden on healthcare systems. The limited availability of Visudyne has impacted the planning, prioritisation and prescribing of patient treatment. Once the shortage is fully resolved, EMA’s shortage catalogue will be updated.
This is an extract. The publication continues at the source.
Source: European Medicines Agency.
Read the original at the source: https://www.ema.europa.eu/en/news/new-eu-supply-chain-end-visudyne-shortage
Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- European Medicines Agency — imported from official source
- Official source
- https://www.ema.europa.eu/en/news.xml RSS
- Imported
- October 03, 2026 20:30
- Versions
- 1 recorded
- Identity
-
https://www.ema.europa.eu/en/news/new-eu-supply-chain-end-visudyne-shortage